Aventis Pharma Deutschland, Gmbh

Aventis Pharmaceuticals Inc.

Lexicon Pharmaceuticals, Inc.

Coelacanth Corporation

Gerard M McGeehan

Robert D Groneberg

Richard F Labaudiniere

Michael F Kelley

Zaid Jayyosi

Daniel Gerard McGarry

Hartmuth C Kolb

Anne Minnich

Mark A Bobko

Litao Zhang

Joseph M Salvino

Zhi-Cai Shi

Robert L Morris

Gregory Bernard Poli

Thomas Caulfield

Cullen Cavallaro

John E Airey

Fran&ccedil;ois-Fr&eacute;d&eacute;ric Clerc

Daniel No&euml;l Andr&eacute; Bezard

Thomas J Caulfield

Laxma Reddy Kolla

The use of triaryl acid derivatives of formula (I)and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

Therapeutic uses of tri-aryl acid derivatives

PPAR-&ggr; agonists as agents for the treatment of type II diabetes

This invention is directed to a fluorophenyl resin compound, to methods of its preparation; and to its use in the solid phase synthesis of amides, peptides, hydroxamic acids, amines, urethanes, carbonates carbamates, sulfonamides and &agr;-substituted carbonyl compounds.

Fluorophenyl resin compounds

Therapeutic uses of di-aryl acid derivatives

Disclosed are novel compounds of which function as a sulfonyl linker between a target molecule and a polymer solid support, novel sulfonyl aziridine scaffold intermediates to optimize the regioselectivity associated with the nucleophilic substitution of these aziridines, a method for making derivatized aziridine, and a method for making derivatized amines.

Sulfonyl linker for the creation of libraries via immobilization of amines

A method for mediating the activity of PPAR-&ggr; receptor comprising contacting said PPAR-&ggr; receptor with a compound of formula I defined herein. Also disclosed is the treatment of a patient suffering from a physiological disorder capable of being modulated by a compound of formula I having PPAR-&ggr; ligand binding activity, comprising administering to the patient a pharmaceutically acceptable amount of the compound, or a pharmaceutically acceptable salt thereof.

Therapeutic uses of quinoline derivatives

Growing community of inventors

Chester Springs, PA, United States of America

Gerard M McGeehan